TITLE

Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model

AUTHOR(S)
Rozenbaum, Mark H.; Mangen, Marie-Josee J.; Giaquinto, Carlo; Wilschut, Jan C.; Hak, Eelko; Postma, Maarten J.
PUB. DATE
January 2011
SOURCE
BMC Public Health;2011 Supplement 4, Vol. 11 Issue Suppl 4, p462
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Each year rotavirus gastroenteritis results in thousands of paediatric hospitalisations and primary care visits in the Netherlands. While two vaccines against rotavirus are registered, routine immunisation of infants has not yet been implemented. Existing cost-effectiveness studies showed inconsistent results for these vaccines because of lack of consensus on the impact. We aimed to investigate which factors had a major impact on costeffectiveness and were primarily responsible for the large differences in previously estimated cost-effectiveness ratios. Methods: Based on updated data on health outcomes and cost estimates, we re-assessed the cost-effectiveness of routine paediatric rotavirus vaccination within the National Immunization Program for the Netherlands. Two consensus meetings were organised with national and international experts in the field to achieve consensus and resolve potential controversies. Results: It was estimated that rotavirus vaccination in the Netherlands could avert 34,214 cases of rotavirus gastroenteritis in children aged less than 5 years. Notably, 2,779 hospitalisations were averted of which 315 were extensions of existing hospital stays due to nosocomial rotavirus infection. With a threshold varying from 20K€ - 50K€ per QALY and according to the base-case scenario, the full vaccination costs per child leading to costeffectiveness was €57.76 -€77.71. Results were sensitive to the inclusion of potential vaccine induced herd protection, QALY losses and number of deaths associated with rotavirus gastroenteritis. Conclusions: Our economic analysis indicates that inclusion of rotavirus vaccination in the Dutch National Immunization Program might be cost-effective depending on the cost of the vaccine and the impact of rotavirus gastroenteritis on children's quality of life.
ACCESSION #
62668340

 

Related Articles

  • Cost-Effectiveness of Rotavirus Vaccination in Peru. Clark, Andrew D.; Walker, Damian G.; Mosqueira, N. Rocio; Penny, Mary E.; Lanata, Claudio F.; Fox-Rushby, Julia; Sanderso, Colin F. B. // Journal of Infectious Diseases;11/2/2009, Vol. 200 Issue S1, pS114 

    Background. There are plans to introduce the oral rotavirus vaccine Rotarix (GlaxoSmithKline), 1 of 2 recently developed vaccines against rotavirus, in Peru. Methods. We modeled the cost-effectiveness of adding a rotavirus vaccine to the Peruvian immunization program under 3 scenarios for the...

  • Reviewing the Cost Effectiveness of Rotavirus Vaccination. Bilcke, Joke; Beutels, Philippe // PharmacoEconomics;2009, Vol. 27 Issue 4, p281 

    Published health economic evaluations of rotavirus vaccination up until July 2008 were reviewed. We assess whether differences in the results and conclusions of the various studies are due to differences in methodological and modelling choices, and/or the way parameter uncertainty was taken into...

  • Rotavirus vaccination not economically viable in Thailand.  // PharmacoEconomics & Outcomes News;3/17/2012, Issue 649, p9 

    The article discusses a study on the cost-effectiveness of infant rotavirus vaccination in Thailand.

  • Chinese study: Universal rotavirus immunization may be cost-effective.  // Infectious Disease News;Nov2009, Vol. 22 Issue 11, p36 

    This article focuses on a study which examined the cost-effectiveness of rotavirus immunization in China.

  • Rotavirus vax should be "highly cost-effective" in Bolivia.  // PharmacoEconomics & Outcomes News;7/9/2011, Issue 632, p5 

    This article summarizes a report on the cost effectiveness of universal rotavirus vaccination in Bolivia.

  • Re: “Age Dependence of the Risk of Intussusception Following Tetravalent Rhesus-Human Reassortant Rotavirus Tetravalent Vaccine: Is it Beyond Doubt?”.  // American Journal of Epidemiology;Jul2010, Vol. 172 Issue 1, p125 

    A correction to the article "Age Dependence of the Risk of Intussusception Following Tetravalent Rhesus-Human Reassortant Rotavirus Tetravalent Vaccine: Is It Beyond Doubt?" by J. Chen, J. F. Heyse, P. Heaton and colleagues, is presented.

  • Vaccine success cuts rotavirus illness. Ratcliffe, Lucy // New Zealand Doctor;3/13/2013, p11 

    The article reports on the 71% decrease in hospitalization incidence of patients with rotavirus due to the rotavirus vaccines Rotarix and Rotateq in Australasia.

  • Rotavirus vax economically sound in England and Wales.  // PharmacoEconomics & Outcomes News;10/13/2012, Issue 664, p1 

    The article discusses research on the cost-effectiveness of pentavalent rotavirus vaccination in England and Wales. It references a study by K. E. Atkins and colleagues published in the September 20, 2012 issue of "Vaccine." A 50-year dynamic transmission model to compare the cost effectiveness...

  • Rotavirus vaccination not currently cost effective for kids in France.  // PharmacoEconomics & Outcomes News;1/26/2008, Issue 545, p4 

    The article discusses a research on the costs and cost-effectiveness of childhood vaccination against rotavirus in France. It references a study by H. Melliez and colleagues, published in the January 2008 issue of "Vaccine." The study found that rotavirus vaccination reduces hospitalizations and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics